Adjunctive Therapy in ACS Patients: TRITON-TIMI 38, EVA-AMI, and BRIEF-PCI
Adjunctive Therapy in ACS Patients: TRITON-TIMI 38, EVA-AMI, and BRIEF-PCI
Options for adjunctive therapy in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) continue to be the subject of intense investigation. As presented at the American Heart Association 2007 Scientific Sessions, the 3 trials described below highlight important areas for continued research and clinical practice.
Investigators of the TRITON-TIMI 38 trial, which compared prasugrel with clopidogrel in ACS patients undergoing elective or urgent PCI, found that higher inhibition of platelet activity was associated with significant reductions in clinical endpoints, but regimens were not without their risks. The results of EVA-AMI suggest that eptifibatide is as effective as abciximab as an adjunct to primary PCI. And abbreviated infusions (<2 hours) of eptifibatide following successful nonemergent PCI may safely replace the standard 18-hour infusion in some patients, as shown in the BRIEF-PCI trial.
Introduction
Options for adjunctive therapy in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) continue to be the subject of intense investigation. As presented at the American Heart Association 2007 Scientific Sessions, the 3 trials described below highlight important areas for continued research and clinical practice.
Investigators of the TRITON-TIMI 38 trial, which compared prasugrel with clopidogrel in ACS patients undergoing elective or urgent PCI, found that higher inhibition of platelet activity was associated with significant reductions in clinical endpoints, but regimens were not without their risks. The results of EVA-AMI suggest that eptifibatide is as effective as abciximab as an adjunct to primary PCI. And abbreviated infusions (<2 hours) of eptifibatide following successful nonemergent PCI may safely replace the standard 18-hour infusion in some patients, as shown in the BRIEF-PCI trial.
Source...